Co-Diagnostics (NASDAQ:CODX) Given Neutral Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Co-Diagnostics (NASDAQ:CODX) in a research report sent to investors on Monday,Benzinga reports.

A number of other analysts have also recently weighed in on CODX. Weiss Ratings restated a “sell (d-)” rating on shares of Co-Diagnostics in a report on Thursday, October 30th. Wall Street Zen upgraded shares of Co-Diagnostics to a “hold” rating in a research note on Saturday, November 1st. Finally, D. Boral Capital reissued a “buy” rating and issued a $3.00 price objective on shares of Co-Diagnostics in a research report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $2.00.

Co-Diagnostics Trading Down 4.7%

Shares of NASDAQ:CODX opened at $0.33 on Monday. The company has a market capitalization of $20.32 million, a PE ratio of -0.34 and a beta of 0.97. Co-Diagnostics has a 12-month low of $0.23 and a 12-month high of $1.55. The business’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.33.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Co-Diagnostics had a negative return on equity of 70.26% and a negative net margin of 6,347.34%.The firm had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Research analysts predict that Co-Diagnostics will post -1.22 EPS for the current year.

Hedge Funds Weigh In On Co-Diagnostics

An institutional investor recently raised its position in Co-Diagnostics stock. Virtu Financial LLC grew its position in Co-Diagnostics, Inc. (NASDAQ:CODX) by 393.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 126,524 shares of the company’s stock after purchasing an additional 100,901 shares during the period. Virtu Financial LLC owned approximately 0.21% of Co-Diagnostics worth $44,000 at the end of the most recent quarter. 14.99% of the stock is owned by institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.